Evidence map›Paper›PMID 38117449›Full record

Trial reportAIDS and behavior2024

Long-Term Effects of Incentives for HIV Viral Suppression: A Randomized Clinical Trial.

Matthew D Novak, August F Holtyn, Forrest Toegel, Andrew M Rodewald, Jeannie-Marie Leoutsakos, Michael Fingerhood, Kenneth Silverman

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02363387 (Suppression of HIV 1 RNA in People Living With HIV), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02363387 nacompletednot on this map

Suppression of HIV 1 RNA in People Living With HIV

TypeinterventionalSponsorJohns Hopkins UniversityRan2015 to 2021Enrolled102ConditionsHIVArmsIncentives for Viral Suppression, Standard HIV Medical Care
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew D NovakDepartment of Psychiatry and Behavioral Sciences, Center for Learning and Health, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 350 East, Baltimore, MD, 21224, USA.
August F HoltynDepartment of Psychiatry and Behavioral Sciences, Center for Learning and Health, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 350 East, Baltimore, MD, 21224, USA.
Forrest ToegelDepartment of Psychiatry and Behavioral Sciences, Center for Learning and Health, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 350 East, Baltimore, MD, 21224, USA.
Andrew M RodewaldDepartment of Psychiatry and Behavioral Sciences, Center for Learning and Health, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 350 East, Baltimore, MD, 21224, USA.
Jeannie-Marie LeoutsakosDepartment of Psychiatry and Behavioral Sciences, Center for Learning and Health, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 350 East, Baltimore, MD, 21224, USA.
Michael FingerhoodDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kenneth SilvermanDepartment of Psychiatry and Behavioral Sciences, Center for Learning and Health, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 350 East, Baltimore, MD, 21224, USA. ksilverm@jhmi.edu.

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Incentives for Suppression of HIV-1 RNA in People Living with HIVR01AI117065 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILVERMAN, KENNETH · 2015 to 2019
$3.8M
NIAID NIH HHS R01 AI117065NIDA NIH HHS T32 DA007209NIDA NIH HHS T32DA07209
6 · The paper itself

Abstract

Achieving viral suppression in people living with HIV improves their quality of life and can help end the HIV/AIDS epidemic. However, few interventions have successfully promoted HIV viral suppression. The purpose of this study was to evaluate the long-term effectiveness of financial incentives for viral suppression in people living with HIV. People living with a detectable HIV viral load (≥ 200 copies/mL) were randomly assigned to Usual Care (n = 50) or Incentive (n = 52) groups. Incentive participants earned up to $10 per day for providing blood samples with an undetectable or reduced viral load. During the 2-year intervention period, the percentage of blood samples with a suppressed viral load was significantly higher among Incentive participants (70%) than Usual Care participants (43%) (OR = 7.1, 95% CI 2.7 to 18.8, p < .001). This effect did not maintain after incentives were discontinued. These findings suggest that frequent delivery of large-magnitude financial incentives for viral suppression can produce large and long-lasting improvements in viral load in people living with HIV. ClinicalTrials.gov Identifier: NCT02363387.

Indexed as

Acquired Immunodeficiency SyndromeAnti-HIV AgentsHIV InfectionsHumansMotivationQuality of LifeViral LoadAnti-HIV AgentsContingency managementHIVIncentivesMedication adherenceViral suppression

Identifiers

PMID38117449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.